Last reviewed · How we verify
paclitaxel plus carboplatin
Paclitaxel works by inhibiting cell division, while carboplatin interferes with DNA repair, both leading to cell death in rapidly dividing cancer cells.
Paclitaxel works by inhibiting cell division, while carboplatin interferes with DNA repair, both leading to cell death in rapidly dividing cancer cells. Used for Non-small cell lung cancer, Ovarian cancer, Breast cancer.
At a glance
| Generic name | paclitaxel plus carboplatin |
|---|---|
| Also known as | Carbo/Taxol®, Taxol |
| Sponsor | Immatics US, Inc. |
| Drug class | Taxane and platinum-based chemotherapy |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
Paclitaxel binds to tubulin, preventing microtubule formation and cell division. Carboplatin forms platinum-DNA adducts, which interfere with DNA repair and induce apoptosis in cancer cells.
Approved indications
- Non-small cell lung cancer
- Ovarian cancer
- Breast cancer
Common side effects
- Neutropenia
- Anemia
- Thrombocytopenia
- Nausea and vomiting
- Diarrhea
- Fatigue
- Hair loss
- Peripheral neuropathy
- Infection
- Hypersensitivity reaction
Key clinical trials
- Durvalumab in Combination With Chemotherapy in Treating Patients With Advanced Solid Tumors, DURVA+ Trial (PHASE2)
- Paclitaxel and Carboplatin With or Without Bevacizumab in Treating Patients With Stage II, Stage III, or Stage IV Ovarian Epithelial Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer (PHASE3)
- Reduced-dose Carboplatin-doublet-chemotherapy + Cemiplimab vs Cemiplimab Monotherapy in Treatment Naive Older and Frail Patients With Metastatic NSCLC With PD-L1 <50% (PHASE2)
- A Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Participants With Triple-Negative Breast Cancer (MK-2870-011/TroFuse-011) (PHASE3)
- A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032) (PHASE3)
- Testing the Addition of an Individualized Vaccine to Durvalumab and Tremelimumab and Chemotherapy in Patients With Metastatic Triple Negative Breast Cancer (PHASE2)
- Testing the Addition of an Antiangiogenic Drug (Bevacizumab) to Chemotherapy (Carboplatin and Paclitaxel) Combined With Immunotherapy (Pembrolizumab) for pMMR, TP53 Mutated Endometrial Cancer (PHASE3)
- Pembrolizumab With or Without Maintenance Sacituzumab Tirumotecan (Sac-TMT; MK-2870) in Metastatic Squamous Non-small Cell Lung Cancer (NSCLC) [MK-2870-023] (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- paclitaxel plus carboplatin CI brief — competitive landscape report
- paclitaxel plus carboplatin updates RSS · CI watch RSS
- Immatics US, Inc. portfolio CI